{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.7","upperLimit":"92.9","value":"87.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"ORR is the proportion of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or PR as determined by investigator using the International Myeloma Working Group (IMWG) response criteria.\n\nSCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \\< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \\< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.","dispersionType":"70% Confidence Interval","groups":[{"description":"Lenalidomide\n\n25 mg taken orally once daily, Days 1 - 21 of each cycle\n\nDexamethasone\n\nAdministered on Days 1, 8, 15, and 22 of each cycle:\n\nOn weeks when elotuzumab is administered:\n\n* 28 mg taken orally (3 - 24 hours prior to start of elotuzumab infusion) AND\n* 8 mg IV (at least 45 minutes prior to elotuzumab administration)\n\nOn weeks when elotuzumab is NOT administered:\n\n\\- 40 mg taken orally\n\nElotuzumab (BMS-901608)\n\n* Cycle 1 - 2: 10 mg/kg IV, Days 1, 8, 15, 22\n* Cycle 3 - 18: 10 mg/kg IV, Days 1 and 15\n* Cycle 19 and beyond: 20 mg/kg IV, Day 1","id":"OG000","title":"Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)"}],"paramType":"NUMBER","populationDescription":"Participants treated with E-Ld","reportingStatus":"POSTED","timeFrame":"From first dose until documented response (assessed up to February 2017, approximately 24 months)","title":"Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}